CME Group (NASDAQ:CME)’s new legal entity CME Amsterdam B.V. will be fully operational from 18 March 2019, since the approval from the Dutch Minister of Finance is already a fact.
The newly formed Amsterdam establishment will ensure that CME Group’s BrokerTec and EBS venues and CME Regulatory Reporting services (formerly NEX Regulatory Reporting) can continue to service their EU27 clients, regardless of Brexit’s outcome.
The following businesses will be transitioned to CME Amsterdam:
- B.V. – BrokerTec’s European Government Bond
- European Repo businesses (under a new Regulated Market licence)
- on-MTF FX forwards and swaps (under a new MTF licence), to maintain a single pool of liquidity.
- CME Regulatory Reporting Approved Publication Arrangement (APA)
- Approved Reporting Mechanism (ARM) trade and transaction reporting services
BrokerTec’s UK Gilts and Gilt Repo businesses and all other EBS businesses, will continue to operate with no change.
CME Amsterdam B.V. will operate alongside Abide Financial DRSP Limited (AFDL), which is authorised as an ARM and APA by the UK FCA and will continue to provide these services to UK clients.